Viemed Healthcare, Inc. reported significant financial growth in its latest quarterly filing, with revenues reaching $71.9 million for the three months ended September 30, 2025, marking a 24% increase from $58.0 million in the same period last year. For the nine months ending September 30, 2025, total revenue was $194.1 million, an 18.7% increase compared to $163.6 million in 2024. The company's net income for the third quarter was $3.6 million, a decrease from $3.9 million in the prior year, while net income for the nine-month period rose to $9.6 million, up 36.9% from $7.0 million in 2024.
The increase in revenue was primarily driven by a substantial rise in equipment and supply sales, which surged by 86% to $15.7 million in the third quarter, largely attributed to the success of the sleep resupply program and the addition of maternal health services following the acquisition of Lehan Drugs, Inc. on July 1, 2025. Ventilator rental revenue also contributed to growth, increasing by 9.8% to $34.9 million, supported by higher patient volumes. The company’s gross profit margin, however, saw a slight decline to 57.5% from 59.3% year-over-year, reflecting changes in the revenue mix.
In terms of operational metrics, Viemed Healthcare employed 414 licensed respiratory therapists as of September 30, 2025, which represents approximately 30% of its total workforce. The company continues to expand its geographic footprint, serving patients across all 50 states. The acquisition of Lehan is expected to enhance operational synergies and expand Viemed's market presence in the Midwest, with goodwill from the acquisition amounting to $25.5 million.
The company’s total assets increased to $202.4 million as of September 30, 2025, up from $177.1 million at the end of 2024, driven by the acquisition and growth in accounts receivable. Current liabilities also rose to $44.2 million, reflecting increased operational activity and the impact of the acquisition. Viemed's cash and cash equivalents decreased to $11.1 million from $17.5 million at the end of 2024, primarily due to cash used in investing activities related to the acquisition and capital expenditures.
Looking ahead, Viemed Healthcare anticipates continued growth driven by the increasing demand for home medical equipment and services, particularly in the respiratory care segment. The company is focused on expanding its service areas and enhancing its product offerings, which it believes will further solidify its position in the market. The ongoing trend towards home-based healthcare solutions is expected to provide additional opportunities for growth, aligning with the company's strategic objectives.
About VIEMED HEALTHCARE, INC.
Viemed Healthcare, Inc. provides home medical equipment and respiratory healthcare services across the U.S., focusing on in-home treatment for respiratory diseases. Its offerings include ventilators, oxygen therapy, sleep testing, and staffing services. Serving primarily Medicare and private insurers, Viemed emphasizes cost-effective, high-quality care, leveraging clinical expertise and technology to support patient health while navigating complex regulatory and reimbursement environments.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.